US FDA approves AstraZeneca’s diabetes drug for treating heart failure risk Reuters Oct 21, 2019 The approval by the US Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial
FDA gives fast track status to AstraZeneca’s diabetes drug Farxiga Reuters Aug 27, 2019 In July, the US regulators had declined to approve Farxiga as a supplement to insulin in adults with type-1 diabetes where insulin…
AstraZeneca’s Farxiga meets main goal of heart failure study Reuters Aug 20, 2019 Farxiga belongs to a class of medicines called SGLT2 inhibitors, which control blood sugar levels by causing the kidneys to expel…